"You have success rates that haven't improved in 30 years, " says Amgen research chief Roger Perlmutter, a former Merck researcher, in the current issue of Forbes (see: " Storm Warnings").

FORBES: The Best-Selling Drugs In America

My exclusive article in the current issue of Forbes Magazine takes a detailed look inside GSK to see whether the strategy will work.

FORBES: Exclusive: Glaxo's Witty On Why He Shuns Megadeals